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A B S T R A C T
Interferon (IFN)-α treatment for hepatitis C virus (HCV) is a well-recognized clinical model for inflammation-
induced depression, but the brain cellular mechanisms underlying these effects are still not clear. Previous data
reported an alteration in peripheral levels of inflammatory and neuroplasticity markers in the blood of depressed
versus non-depressed patients. We investigated the in vitro effect of serum from depressed and non-depressed
HCV patients (at baseline, before IFN-α; and after four weeks of IFN-α), on the apoptotic and neurogenic pro-
cesses in a human hippocampal progenitor cells model. Results show that higher apoptosis during proliferation
observed upon treatment of cells with baseline serum, and lower neuronal differentiation observed upon
treatment with serum after 4 weeks of IFN-α, were predictive of later development of IFN-α–induced depression
(odds ratio= 1.26, p=0.06, and=0.80, p=0.01, respectively). While serum after IFN-α increased neuro-
genesis compared with baseline serum, a lower increase in neurogenesis was also predictive of later development
of depression (odds ratio= 0.86; p= 0.006). Our results provide evidence for the fundamental role of the
systemic milieu (captured by serum samples) in the regulation of hippocampal neurogenesis by inflammation, a
putative mechanism involved in the development of neuropsychiatric conditions.
1. Introduction
Approximately 200,000 individuals have chronic hepatitis C virus
(HCV) in the UK, and 170 million worldwide (Harris et al., 2012). The
current standard treatment for HCV infection involves subcutaneous
injection with pegylated-interferon-alpha (peg-IFN-α), which clear the
virus in up to 80% of patients while inducing a number of side effects
(Wichers and Maes, 2002). Indeed, despite the efficacy of this treat-
ment, IFN-α promotes depression in up to 35% of patients within the
first 8 to 12 weeks of the therapy (Asnis and De La Garza, 2006;
Capuron and Miller, 2004; Machado et al., 2017), as well as other side
effects, including symptoms of anxiety, mania and fatigue (Sockalingam
and Abbey, 2009). The brain cellular mechanisms underlying this as-
sociation have not been completely elucidated yet.
Our work as well as previous evidence have reported that peripheral
IFN-α acutely induces the production and release of several innate
immune cytokine proteins (Hepgul et al., 2016; Raison et al., 2010).
These cytokines are putatively involved in the depressogenic action of
IFN-α. Higher serum or plasma levels of pro-inflammatory markers
have been shown to be associated with an increased risk of major
depressive disorder (Dowlati et al., 2010). Another study from our
group provided evidence for increased inflammation in the blood of
depressed patients when compared with healthy controls, together with
an association between higher cytokine levels and lack of anti-
depressant response (Cattaneo et al., 2010). However, it is still unclear
how these factors contained in peripheral blood can affect the brain and
ultimately predispose the individual to the development of depression.
Several pathways through which peripheral blood factors, including
inflammatory molecules, can be transmitted from the periphery to the
brain have been investigated (Louveau et al., 2015). Previous studies
have demonstrated that distinct cytokines, including interleukin-1beta
(IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α), known to be
upregulated both in the periphery and in the brain of patients with
major depressive disorder (MDD), are able to increase blood brain
barrier (BBB) permeability (Deli et al., 1995; Didier et al., 2003;
Schwaninger et al., 1999) and ultimately to cause changes in discrete
brain regions, including the hippocampus (Wang et al., 2008). This
region is highly involved in the process of neurogenesis, which in hu-
mans principally occurs in the subventricular zone (SVZ) of the lateral
ventricles and the sub-granular zone (SGZ) of the dentate gyrus (DG) of
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the hippocampus (Kempermann et al., 2018). Of relevance, previous
research has demonstrated that peripheral administration of IFN-α or
other cytokines, such as C-C motif chemokine ligand 11 (CCL11), in-
duce depressive-like behaviours in rodents, affecting both cell pro-
liferation and neuronal differentiation (Villeda et al., 2011, 2014;
Zheng et al., 2014). Taken together, these findings indicate that distinct
factors contained in the circulatory systemic environment may affect
the brain, and that the psychiatric side effects caused by IFN-α therapy
might be a consequence of those factors to access the brain, and to
disrupt neurogenesis or neuronal function in the hippocampus.
To investigate the contributing role of the systemic milieu in the
regulation of hippocampal neurogenesis we used our previously es-
tablished human hippocampal progenitor cell (HPC) line (Anacker
et al., 2013a; Borsini et al., 2017b, 2018; Zunszain et al., 2012), and
examined the effect of treatment with serum samples from patients with
HCV, before and after 4 weeks of IFN-α, on the neurogenic process. In
particular, we investigated whether changes in proliferation, neuro-
genesis and apoptosis, caused by treatment with serum samples, were
predictive of later development of IFN-α–induced depression.
2. Method
2.1. Patients cohort
The sub-group of patients, from which serum samples derived, is
part of bigger cohort of patients recruited from the outpatient liver
department of King’s College Hospital and St George’s Hospital. Eligible
patients were adult patients with chronic HCV infection who were due
to commence combination antiviral therapy with IFN-α and ribavirin
without any additional direct-acting antiviral (boceprevir, telaprevir or
simeprevir). The whole cohort of patients received combination therapy
for at least 24 weeks. Patients were assessed at baseline when starting
IFN-α treatment (TW0) and monthly for the first three months, at TW4,
8, 12, and 16 then two-monthly thereafter until the end of their treat-
ment, at TW24. Combination therapy comprised of weekly sub-
cutaneous IFN-α injections (1.5 µg per kg of body weight) and daily
ribavirin tablets (800–1400mg orally per day in 2 divided doses).
Exclusion criteria for the larger cohort included, and for whom we had
blood samples at both TW0 and TW4: a total of 33 eligible patients were
included. The study was approved by the King’s College Hospital
Research Ethics Committee (Ref: 10/H0808/30).
2.2. Demographics and clinical data of the IFN-α-treated HCV cohort
The Medical Research Council (MRC) Socio-demographic Schedule
(Mallett et al., 2002) was administered at TW0 to collect socio-demo-
graphic data, including age and gender. The Mini-International Neu-
ropsychiatric Interview (MINI) questionnaire (Sheehan et al., 1998)
was administered at TW0, in order assess patients for a current de-
pressive episode, as well as at follow-up assessments (TW4, 8, 12 and
24) to detect new onset cases of depression during IFN-α therapy. De-
mographic data shows that the selected cohort of 33 patients is pre-
dominantly characterised by male subjects (78.8%) with no significant
difference in terms of age (Table 1). With respect to clinical data, 9
patients (27.3%) developed depression during IFN-α treatment, and 24
patients (72.7%) did not. Most importantly, the 9 patients developed
depression between TW8 and TW24 (Table 2), that is, were not yet
depressed at the time of the second (TW4) serum sample used for the
present study.
2.3. Human hippocampal progenitor cells
For the in vitro experiments with serum from IFN-α-treated HCV
patients, multipotent human hippocampal progenitor cell line
HPC0A07/03C, kindly provided by ReNeuron Ltd (Surrey, UK) was
used. Cells were grown as previously described in RMM consisting of
Dulbecco’s Modified Eagle’s Media/F12 (DMEM:F12, Invitrogen,
Paisley, UK) supplemented with 0.03% human albumin (Baxter
Healthcare, Compton, UK), 100 µg/mL human apo-transferrin, 16.2 µg/
mL human putrescine diHCl, 5 µg/mL human recombinant insulin,
60 ng/mL progesterone, 2mM L-glutamine and 40 ng/mL sodium se-
lenite (Anacker et al., 2013a, 2013b, 2011; Borsini et al., 2017a, 2018;
Zunszain et al., 2012). To maintain proliferation, 10 ng/mL human
basic fibroblast growth factor (bFGF), 20 ng/mL human epidermal
growth factor (EGF) and 100 nM 4-hydroxytamoxifen (4-OHT) were
added. Cells were grown in 75 cm2 filtered cap culture flasks (Nunclon,
Roskilde, Denmark) at 37 °C in 5% CO2 and regularly passaged at 80%
confluence, until being transferred to plates for the differentiation ex-
periments.
2.4. Proliferation, neurogenesis and apoptosis
In order to assess proliferation and apoptosis (during the pro-
liferation stage) progenitor cells were plated on 96-well plates
(Nunclon) at a density of 1.2× 104 cells per well per well in 100 μl
RMM media. Cells were cultured in the presence of EGF, bFGF and 4-
OHT for 24 h followed by 2 days incubation with 1% serum samples
(the same concentration previously used in the lab as able to induce a
profound effect without causing over-confluence or any alteration in
the composition of neurons) from depressed or non-depressed IFN-α-
treated HCV patients, also in the presence of growth factors containing
0.5 mg/ml penicillin streptomycin. The synthetic nucleotide bromo-
deoxyuridine (BrdU) (B5002, Sigma) with a final concentration of
10 μM was added to the media 4hrs before the end of the incubation to
label proliferating cells.
Whereas, in order to assess neuronal differentiation and apoptosis
(during the differentiation stage) cells were plated on 96-well plates
(Nunclon) at a density of 1.2× 104 cells per well per well in 100 μl
RMM media. Following the proliferation phase previously described,
cells were washed twice for 15min in RMM media (without EGF, bFGF
and 4-OHT), and then cultured with 1% serum samples from depressed
or non-depressed IFN-α–treated HCV patients in RMM containing
0.5 mg/ml penicillin streptomycin for subsequent 7 days.
Table 1
Characteristics of interferon-alpha (IFN-α) treated Hepatitis C (HCV) depressed
vs. non-depressed patients assessed at baseline.
Depressed (n= 9) Non-depressed (n=24)
(n=18)
p value
Age (years)
Mean ± SEM 41.3 ± 5.3 41.6 ± 2.5 p=0.9*
Gender
Male 8 (88.8%) 18 (75%) p= 0.4**
* Student’s t-test.
** Chi squared test.
Table 2
Development of depression during interferon-alpha (IFN-α) treatment.
IFN-α–induced Depression Total Number of
Patients
No Yes
DEPRESSION WEEK None 24 0 24
TW 8 0 5 5
TW 12 0 2 2
TW 16 0 1 1
TW 24 0 1 1
Total Number of Patients 24 9 33
Treatment week (TW).
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2.5. Immunocytochemistry
At the end of the total incubation time, 2 days (proliferation) and
9 days (2 days proliferation followed by 7 days differentiation), cells
were fixed with 4% paraformaldehyde (PFA) for 20min at room tem-
perature. Cells were then washed three times in phosphate-buffered
saline (PBS) and stored at 4 °C in PBS in preparation for im-
munocytochemistry. Subsequently, PFA-fixed proliferating cells pulsed
with BrdU were first incubated with 2 N hydrochloric acid for 25min at
room temperature followed by neutralisation with 0.1M borate buffer
for 10min and 2 washes with PBS. Subsequently, both proliferating and
differentiating cells were incubated in 50 µl of blocking solution con-
stituted of 5% normal donkey serum (D9663, Sigma) in PBS containing
0.3% Triton X-100 (T8787, Sigma) for 1 h at room temperature.
Primary antibodies for BrdU and Ki67 were used to assess proliferation
(rat anti-BrdU, 1:500, Serotec; rabbit anti-Ki67, 1:500, Abcam).
Antibodies for doublecortin (DCX) and microtubulin-associated protein-
2 (MAP2) were used to assess neuroblasts and neurons respectively
(rabbit anti-DCX, 1:500; mouse anti-MAP2, 1:500, Abcam), whereas
antibody for caspase 3 (CC3) (rabbit anti-CC3, 1:500, Cell Signalling)
were used to assess apoptosis and were diluted in blocking solution
buffer. Finally, 30 µl/well were added and left at 4 °C overnight. The
next day, cells were washed, incubated in blocking solution for 30min
and then with fluorescently tagged secondary antibodies for BrdU
(Alexa Fluor 488 donkey anti-rat, 1:1000), Ki67 and CC3 (proliferation)
(Alexa Fluor 555 donkey anti-rabbit, 1:1000), DCX and CC3 (differ-
entiation) (Alexa Fluor 488 donkey anti-rabbit, 1:1000), and MAP2
(Alexa Fluor 555 donkey anti-mouse, 1:1000; all from Life
Technologies) at 30 µl/well for 2 h at room temperature. After 3 washes
with PBS, cells were stained with 0.02mg/ml DAPI at 50 µl/well for
5min and washed 3 more times.
2.6. Automated quantification of immunofluorescence
An unbiased and automated approach was employed to quantify cell
number, cell proliferation, differentiation and apoptosis using the
Fig. 1. Baseline markers of proliferation and apoptosis as predictors of interferon-alpha (IFN-α)–induced depression. Main predictive outcomes of baseline pro-
liferating and apoptotic markers on later IFN-α–induced depression (a). Representative images of cells treated with baseline serum from depressed and non-depressed
patients. Apoptotic cells were stained with caspase 3 (CC3) (red labelling), and apoptotic cells expressing the proliferating marker bromodeoxyuridine (BrdU) (green
labelling) were identified as CC3/BrdU (b). Receiver Operating Characteristic (ROC) curves of baseline CC3 and CC3/BrdU predictors of IFN-α–induced depression
(c). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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CellInsight* NXT High Content Screening (HCS) Platform
(ThermoScientific). The specific paradigms for cellular markers were
based on two BioApplications available in the Cell Insight machine
software: (1) Target Activation, which allows for the quantification of
nuclear markers (DAPI, BrdU and Ki67) and (2) Cell Health Profiling
which enables quantification of markers expressed in the cell body and
dendrites (DCX, MAP2 and CC3). Finally, the overall number of BrdU,
Ki67, DCX, MAP2 and CC3 positive cells over DAPI positive cells were
quantified.
2.7. Statistical analysis
Analysis were performed using IBM SPSS statistical software version
22 and StataCorp STATA version 13. Non-parametric Mann-Whitney U
and Wilcoxon test, and Chi-squared test were used to investigate dif-
ferences in the demographics of depressed and non-depressed patients,
and for differences in the expression of proliferation and differentiation
markers between depressed and non-depressed, at baseline and TW4.
Spearman’s rs test was used to investigate correlations among the
markers. Binary logistic regression was used when assessing the pre-
dictive effect of TW0 and TW4 immunostaining outcomes with later
IFN-α–induced depression.
3. Results
Details on descriptive statistics (mean ± SD) and analysis of dif-
ferences for each marker at TW0 and TW4, comparing depressed with
non-depressed patients, are presented in the Supplementary Table 1.
Notably, patients who developed IFN-α–induced depression had a sig-
nificantly higher number of apoptotic (CC3+ and CC3/Brdu+) cells at
TW0, but not at TW4, and a significantly lower number of neuroblast
(DCX+) cells at TW4, but not at TW0 (Supplementary Table 1). While
serum from all patients increased the number of DCX+ cells and neu-
ronal (MAP2+) cells between TW0 and TW4, patients who developed
IFN-α–induced depression had a significantly lower increase in the
number of DCX+ cells between TW0 and TW4 (Supplementary
Table 1).
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.bbi.2019.06.018.
Of note, all patients developed depression between TW8 and TW24
(Table 2); thus, our analysis focused on predicting the development of
(later) IFN-α–induced depression, through a series of logistic regres-
sions.
3.1. Higher baseline apoptosis predicts later IFN-α–induced depression
3.1.1. Proliferation and apoptosis
We first assessed whether any changes in proliferating or apoptotic
markers, detected upon treatment with TW0 serum samples, were able
to predict later IFN-α–induced depression. When entering separately
each marker in the model, results show no effect of baseline pro-
liferating markers (BrdU and Ki67) in predicting IFN-α–induced de-
pression (Fig. 1a). However, a baseline higher number of apoptotic
CC3+ cells, and of proliferating cells undergoing apoptosis, CC3/BrdU
+ cells, significantly predicted depression. In particular, for a one-unit
increase in the number of TW0 CC3+ cells, and of TW0 CC3/BrdU+
cells, there is respectively 26% and 54% increase in the odds of be-
coming depressed (respectively, odds ratio= 1.26, p= 0.03; odds
ratio= 1.54, p= 0.02; Fig. 1a and b).
Subsequently, in order to test the accuracy of the model with CC3
and CC3/BrdU as predictors, we plotted the true positive values
(Specificity) against the false positive values (Sensitivity) using the
Receiver Operating Characteristic (ROC) curve. Since CC3 is highly
correlated with CC3/BrdU (rs= 0.9, p < 0.0001), we generated two
independent models and ROC curves. Results show that the models with
TW0 CC3 and TW0 CC3/BrdU as variables are respectively 77% and
81% accurate in predicting later development of depression (Fig. 1c).
3.1.2. Differentiation and apoptosis
Having shown the significant role of changes in the number of
CC3+ cells caused by treatment with baseline serum samples in pre-
dicting IFN-α–induced depression, we subsequently investigated whe-
ther changes in the neurogenic markers DCX and MAP2, as well as the
apoptotic marker CC3 detected during the differentiation stage, were
predictive of later IFN-α–induced depression. When entering separately
each marker in the model, results show no significant effect for any of
those markers (Table 3).
3.2. Lower neurogenesis at TW4 predicts later IFN-α–induced depression
3.2.1. Proliferation and apoptosis
As for data at baseline, we then investigated whether any changes in
proliferating (BrdU and Ki67) or apoptotic (CC3) markers, detected
upon treatment with TW4 serum samples, were able to predict later
IFN-α–induced depression. When entering separately each marker in
the model, results show no significant effect for any of those markers
(Table 4).
3.2.2. Differentiation and apoptosis
Secondly, we assessed whether changes in neurogenic (DCX and
MAP2) and apoptotic markers (CC3) detected upon treatment with TW4
serum samples were able to predict later depression. When entering
separately each marker in the model, results show that for a one-unit
decrease in TW4 DCX+ cells, there is a 20% increment in the odds of
becoming depressed (odds ratio= 0.80; p=0.01; Fig. 2a and b). In
addition, a ROC curve was generated showing that the model with TW4
DCX as variable is 88% accurate in predicting later development of
depression (Fig. 2c).
3.3. A lower increase in neurogenesis between baseline and TW4 predicts
IFN-α–induced depression
3.3.1. Proliferation and apoptosis
Having shown that baseline apoptotic markers are predictors of later
IFN-α–induced depression, we subsequently investigated whether also
changes between TW0 and TW4 in the number of proliferating and
apoptotic cells were predictive of later depression. As before, we
Table 3
Baseline neurogenic and apoptotic markers as predictors of interferon-alpha
(IFN-α)–induced depression.
IFN-α–induced Depression Odds Ratio p value R2
TW0 DCX 1.08 0.3 0.03
TW0 MAP2 1.08 0.4 0.02
TW0 CC3 1.03 0.6 0.006
TW0 CC3/MAP2 0.91 0.7 0.003
Treatment week (TW), doublecortin (DCX), microtubule associated protein 2.
(MAP2), caspase 3 (CC3). Analyses were controlled for age. Pseudo R2 (Cox &
Snell).
Table 4
Treatment week 4 (TW4) proliferating and apoptotic markers as predictors of
interferon-alpha (IFN-α)–induced depression.
IFN-α-induced Depression Odds Ratio p value R2
TW4 BrdU 1.02 0.3 0.03
TW4 Ki67 0.93 0.1 0.08
TW4 CC3 1.05 0.5 0.01
TW4 CC3/BrdU 1.01 0.9 0.0
Treatment week (TW), bromodeoxyuridine (BrdU), caspase 3 (CC3).
Analyses were controlled for age. Pseudo R2 (Cox & Snell).
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focussed on two proliferating markers BrdU and Ki67, and on the
apoptotic marker CC3. Results show no significant effect for any of
those markers on later development of depression (Table 5).
3.3.2. Differentiation and apoptosis
As before, we then investigated whether changes between TW0 and
TW4 also in the number of neurogenic and apoptotic markers were
predictive of later depression.
As mentioned above, DCX+ cells overall tended to increase when
cells were treated with TW4 serum compared with TW0 serum; how-
ever, patients who developed IFN-α–induced depression had a sig-
nificantly lower increase in the number of DCX+ cells between TW0
and TW4 (see Supplementary Table 1).
When entering separately each marker in the model, results show
that a lower increase in DCX+ cells between TW0 and TW4 is pre-
dictive of later development of depression. In particular, for a one-unit
lower in the number of ΔTW4-TW0 DCX+ cells, there is a 14% increment
in the odds of becoming depressed (odds ratio= 0.86, p=0.006;
Fig. 3a and b). In addition, a ROC curve was generated showing that the
model with ΔTW4-TW0 DCX as variable is 89% accurate in predicting
later development of depression (Fig. 3c).
3.4. Low neurogenesis at TW4 and a lower increase in neurogenesis between
baseline and TW4 most accurately predict IFN-α–induced depression
Finally, having discovered that a high number of TW0 CC3+, TW0
CC3/BrdU+, and a low number of TW4 DCX+ and ΔTW4-TW0 DCX+
cells, were significantly predictive of IFN-α–induced depression, we
subsequently investigated which model (containing those markers as
variables) could be defined as the best one in terms of accuracy when
predicting IFN-α–induced depression. Pairwise analysis comparing ROC
curves previously generated from the apoptotic (TW0 CC3 and TW0
CC3/BrdU) and neurogenic (TW4 DCX and ΔTW4-TW0 DCX) markers do
not show any significant difference in the accuracy of predicting IFN-
α–induced depression (respectively, 77%, 81%, 88% and 89% accu-
racy; Fig. 4a and b), even if numerically the TW4 DCX and the ΔTW4-TW0
DCX have the highest predictive values.
4. Discussion
Using a model of inflammation-induced depression, in this study we
provide the first evidence that blood factors, contained in the systemic
milieu of patients receiving chronic treatment with IFN-α, can alter cell
apoptosis and the neurogenic process in vitro, and potentially activate
cellular processes that ultimately may contribute to the development of
IFN-α–induced depression. In particular, we demonstrated that higher
apoptosis upon treatment with baseline (TW0) serum, lower neuro-
genesis upon treatment with TW4 serum, and a lower increase in
neurogenesis between treatments with TW0 and TW4 serum, are pre-
dictive of later development of depression – the last two models with,
Fig. 2. Treatment week 4 (TW4) neurogenic and apoptotic markers as predictors of IFN-α–induced depression. Main predictive outcomes of TW4 neurogenic and
apoptotic markers on later IFN-α–induced depression (a). Representative images of cells treated with TW4 serum from depressed and non-depressed patients.
Neuroblasts were stained with doublecortin (DCX) (green labelling) (b). Receiver Operating Characteristic (ROC) curve of TW4 DCX predictor of IFN-α–induced
depression (c).(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Table 5
Change in proliferating and apoptotic markers between treatment week (TW0)
and TW4 as predictor of interferon-alpha (IFN-α)–induced depression.
IFN-α–induced Depression Odds Ratio p value R2
ΔTW4-TW0 BrdU 0.91 0.82 0.002
ΔTW4-TW0 Ki67 0.93 0.61 0.01
ΔTW4-TW0 CC3 0.95 0.36 0.03
ΔTW4-TW0 CC3/BrdU 0.7 0.055 0.13
Treatment week (TW), bromodeoxyuridine (BrdU), caspase 3 (CC3).
Analyses were controlled for age. Pseudo R2 (Cox & Snell).
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respectively, 88% and 89% accuracy.
Firstly, our findings indicate that baseline peripheral factors can be
predictors of depression when measuring their impact on HPC apop-
tosis. Indeed, although none of the proliferating and neurogenic mar-
kers were affected upon treatment with baseline samples, a high
number of cells positive for the apoptotic marker CC3 was predictive of
later depression. However, using a larger cohort of IFN-α treated HCV
patients (from which we have selected all serum samples used in the
present study) we have found no differences at TW0 in the levels of key
inflammatory cytokines, including IL-1β, IL-6, IL-17 and TNF-α, be-
tween those who later develop or do not develop depression (although,
interestingly, we found differences in the prediction of fatigue) (Hepgul
et al., 2016; Russell et al., 2019). This lack of difference in ‘usual sus-
pect’ cytokines suggests the involvement of other factors contained in
serum from depressed patients that are able to contribute to the in-
crease in cell apoptosis detected in our in vitro study. Indeed, our
transcriptome analysis conducted in the same larger cohort of IFN-α
treated HCV patients revealed the presence of a distinct set of genes
differentially expressed at TW0 between depressed and non-depressed
patients (Hepgul et al., 2016). Among them, ubiquitin-fold modifier 1
(UFM1) and eukaryotic translation initiation factor 4B (EIF4B) were
highly upregulated in patients who developed IFN-α–induced depres-
sion (Hepgul et al., 2016). UFM1 and EIF4B gene belong to respectively,
the oxidative stress response signalling and the rapamycin signalling
pathway, which are associated with regulation of apoptosis, and sy-
naptic plasticity (Chen et al., 2012; Narasimhan et al., 2012), therefore
potentially involved in the detrimental effect seen on cell death upon
treatment with serum from depressed patients.
In this study we also demonstrate that lower levels of neurogenesis
upon treatment with serum at TW4, and a lower increase in neuro-
genesis between TW0 and TW4, are predictive of later development of
depression. Similarly to baseline, results from cytokines analysis con-
ducted in samples from our larger cohort of IFN-α treated HCV patients,
and collected at TW4, did not reveal any differences in the expression of
the candidate cytokines previously mentioned, either as absolute values
at TW4 or as increased between TW0 and TW4 when comparing de-
pressed with non-depressed (Hepgul et al., 2016; Russell et al., 2019).
However, data from our aforementioned transcriptome analysis show
that, at TW4, patients who developed depression had a higher expres-
sion of a distinct set of genes, including cyclin dependent kinase 5
Fig. 3. Changes in neurogenic and apoptotic markers between treatment week 0 (TW0) and TW4 as predictors of IFN-α–induced depression. Main predictive
outcomes of differences in neurogenic and apoptotic markers between TW0 and TW4 on later IFN-α–induced depression (a). Representative images of cells treated
with TW0 and TW4 serum from depressed and non-depressed patients. Neuroblasts were stained with doublecortin (DCX) (green labelling) (b). Receiver Operating
Characteristic (ROC) curve of ΔTW4-TW0 DCX predictor of IFN-α–induced depression (c).
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(CDK5) and CDK8, as well as insulin-like growth factor-binding protein
5 (IGFBP5) and IGFBP7 (Hepgul et al., 2016), which are known to
regulate both cell proliferation and differentiation (Alexander et al.,
2004; Tanno et al., 2005). Furthermore, pathway analysis conducted in
our larger cohort of IFN-α treated patients showed that distinct neu-
roplasticity-related pathways, including extracellular signal-regulated
kinase 5 (ERK5) signaling were modulated in blood of depressed pa-
tients at TW4, when compared with baseline (Hepgul et al., 2016).
ERK5 is a member of the mitogen-activated protein kinase (MAPK)
family, that includes ERK1/2, p38, and JNK, and is known to regulate
neurogenesis (Wang et al., 2014) and to participate in the neuronal
modulation of depression (Todorovic et al., 2009).
We were surprised that treatment with serum collected after
4 weeks of IFN-α treatment (TW4) was able to increase neurogenesis,
since in vitro we found that IFN-α can detrimentally affect neuronal
formation (Borsini et al., 2017c). On possible explanation could be due
to the activation of distinct compensatory mechanisms, which might
have prevented significant damage caused by exposure to serum from
both depressed and non-depressed. Further characterisation of the
cellular mechanisms underlying the effect of IFN-α on neurogenesis are
required, especially upon a longer exposure to IFN-α, in order to
identify potential neuroprotective mechanisms activated only at a later
stage during the treatment.
Of course, this immortalized cell line we used in the study, while
being of invaluable importance for our understanding of molecular
mechanisms occurring in the hippocampal progenitor cells, may differ
from the scenario of an adult in vivo environment and the adult
neurogenic niche, in particular because of the absence of microglia
cells, which are well-known regulators of inflammatory signaling
pathways. However, our previous studies with this in vitro model have
been successfully replicated in animal studies, including changes in
neurogenesis by cortisol, IL-1 and antidepressants, and changes in
stress- and antidepressants-regulated genes (Anacker et al., 2013a,
2013b, 2011; Borsini et al., 2017b; Horowitz et al., 2014; Zunszain
et al., 2012). Therefore, we are confident that our results are relevant to
the human brain.
The number of samples is also very small and collected primarily
from male patients, of whom we have relatively few information with
respect to their clinical profile. Therefore, the predictive models pre-
sented here should be replicated in a large cohort of patients. However,
this was an extremely difficult group of patients to recruit and fur-
thermore, the vast majority of patients recruited had to be excluded due
to our strict criteria (see Methods). These strict criteria however al-
lowed us to eliminate potential confounding factors, which otherwise
might have affected the results. Finally, no control or placebo group
was used for this study. However, the main aim in this case was not to
test the effect of IFN-α on later depression, but instead to identify novel
biological predictors for the development of depression. As such, we
used serum samples of patients who did develop IFN-α-induced de-
pression in comparison with serum samples of patients who did not
develop IFN-α-induced depression.
5. Conclusions
In summary, our in vitro study demonstrates that hippocampal
progenitor cells can be regulated by treatment with serum from IFN-
α–treated HCV patients, and that subsequent alteration in neurogenesis
and in cell survival is predictive of later development of depression. We
believe that these findings may shed light on the pathogenesis of the
depressive disorder, and further propose that the set-up employed in
the present in vitro study, using a human HPCs experimental model
together with a medium-throughput serum screening assay, offers an
excellent opportunity for identification of novel therapeutic strategies
for treatment of neuropsychiatric disorders.
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